Advanced Life Sciences CEO testifies about biothreats

Advanced Life Sciences Holdings, Inc., recently offered testimony at the U.S. Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services hearing titled Defending Against Public Health Threats.

At the hearing, Advanced Life Sciences chairman and chief executive officer Michael Flavin commented on the country’s need to develop late-stage countermeasures to defend against a potential biological attack by terrorists or an emerging health threat.

"Advanced Life Sciences has responded to the critical threat of bioterrorism by developing its novel antibiotic, Restanza, to protect against infection from inhaled anthrax, plague and tularemia," Dr. Flavin said at the hearing. "Consistent with the priorities articulated by HHS, our company is committed to advancing Restanza through the final stage of clinical testing with the goal of gaining FDA approval and providing a safe and effective new countermeasure against lethal pathogens. We intend to continue to explore opportunities to work collaboratively with the US government to protect the public health.”

Secretary of the Department of Health and Human Services Kathleen Sebelius testified at the hearing in support of funding countermeasure developments.

"In today's world, the range of threats is ever-widening to include biological, chemical, nuclear, and radiological hazards in addition to conventional threats," Sebelius testified. "The greatest danger we may face is a microbe that we may have never seen before and for which we do not have a countermeasure. We clearly need the capacity to develop a medical countermeasure quickly."